Latest Market Entry News

Page 1 of 56
WA1 Resources’ pre-feasibility study has put a A$2.5 billion pre-tax NPV on its Luni niobium project, supported by a 20.3 million-tonne Probable Ore Reserve and a proposed 17-year mine life. The numbers are substantial, but construction funding, approvals, offtake and a final investment decision remain ahead.
Maxwell Dee
Maxwell Dee
18 Nov 2026
Imricor Medical Systems (ASX:IMR) has moved from regulatory preparation into US commercial deployment, signing its first two NorthStar hospital customers within weeks of launch. The milestone comes with sharply higher quarterly revenue, a fresh Philips pathway and a still-heavy cash burn.
Victor Sage
Victor Sage
13 Nov 2026
Biome Australia has secured an exclusive mainland China cross-border e-commerce agreement with H&S Global, targeting A$2.0 million in Year 1 purchases from an early 2027 launch. The target is larger than Biome’s entire FY26 international sales, but the company will fund 25% of Year 1 invoiced value in marketing and operational support.
Ada Torres
Ada Torres
9 Nov 2026
Osteopore reported record quarterly revenue of A$859,000 in Q3 CY26 as it added market access in Thailand and Saudi Arabia and completed its first customised Hainan implant. The regenerative implant maker remains cash-flow negative, with A$712,000 in cash and A$14 million still available under its convertible note facility.
Victor Sage
Victor Sage
30 Oct 2026
EBR Systems has submitted its WiSE wireless cardiac pacing system for Australian regulatory approval, opening a potential second commercial market after the United States. The application has entered a priority review pathway, but neither approval nor an assessment timetable is guaranteed.
Victor Sage
Victor Sage
20 Oct 2026
Mayne Pharma has settled its final US Paragraph IV patent dispute over IMVEXXY with Teva, setting a potential generic entry date of 2 September 2032. The agreement removes ongoing litigation without an upfront payment, while leaving court approval and earlier-entry provisions to resolve.
Victor Sage
Victor Sage
16 Oct 2026
Optiscan Imaging has lodged a US FDA 510(k) application for InVue, its precision surgery device designed to provide cellular-level imaging during operations. The submission moves the technology into formal regulatory review, but clearance and commercialisation remain uncertain.
Victor Sage
Victor Sage
5 Oct 2026
Optiscan Imaging has lodged a 510(k) submission for its InForm digital pathology device, moving the product from development into formal US regulatory assessment. FDA clearance is not assured, but a successful determination could open the door to commercial distribution in the company’s target market.
Victor Sage
Victor Sage
1 Oct 2026
Nexsen has proposed a 50:50 joint venture with FlashDx Shenzhen to develop and commercialise an enhanced molecular Group B Streptococcus test, using an existing CE-marked platform as its starting point. The proposed venture could shorten Nexsen’s path into hospital and intrapartum testing across Asia-Pacific, but the term sheet remains non-binding and regulatory work is still ahead.
Victor Sage
Victor Sage
25 Sept 2026
Memphasys says it has identified a potential FDA 510(k) pathway for its Felix sperm separation system, replacing the more complex De Novo route previously contemplated. The company will seek FDA feedback before targeting a formal submission in the first quarter of 2027, while keeping commercial execution focused on existing markets.
Ada Torres
Ada Torres
25 Sept 2026
PaySauce has moved its Global Payroll Platform from development into commercial operation in Australia, while first-quarter FY27 ARR rose 8% to $9.5 million. The expansion is supported by a stronger cash position, but higher customer acquisition costs and lower profitability leave execution firmly in focus.
Victor Sage
Victor Sage
24 Sept 2026
Ventia has secured an extension of its Western Australia Court Security and Custodial Services contract, expected to generate approximately $110 million in revenue through June 2028. The deal provides additional visibility for a long-running government services relationship, although the announcement does not disclose margins or any change to company guidance.
Victor Sage
Victor Sage
23 Sept 2026

Browse the archive

Full archive